Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening

StatusCompleted
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Final enrollment: 6182 participants (planned 5000)
    • Primary and study completion dates changed from estimate of Dec 2025 to Dec 31, 2025
    • Eligibility criteria expanded, about 6 words
    • Site details revised at 2 of 31 sites
    • Publications: details revised at 1 of 1 entry
  2. Trial status: Recruiting to Active, Not Recruiting
    • Primary and study completion dates: Sep 2025 to Dec 2025
    • Site details revised at 31 of 31 sites
    v30
  3. Study sites: 29 to 31v29
  4. Study sites: 27 to 29v28
  5. Study sites: 24 to 27v27
Show 25 earlier versionsHide 25 earlier versions
  1. Primary completion date: Dec 2022 to Sep 2025
    • Study completion date: Apr 2024 to Sep 2025
    v26
  2. Study sites: 23 to 24v25
  3. Study sites: 22 to 23v24
  4. Study sites: 21 to 22v23
  5. Study sites: 20 to 21v22
  6. Study sites: 19 to 20v21
  7. Study sites: 18 to 19v20
  8. Study sites: 17 to 18v19
  9. Study sites: 16 to 17v18
  10. Study sites: 15 to 16v17
  11. Study sites: 14 to 15v16
  12. Study sites: 13 to 14v15
  13. Study sites: 12 to 13v14
  14. Study sites: 11 to 12v13
  15. Study sites: 10 to 11v12
  16. Study sites: 9 to 10v11
  17. Study sites: 8 to 9v10
  18. Study sites: 7 to 8v9
  19. Study sites: 5 to 7v8
  20. Study sites: 4 to 5v7
  21. Study sites: 3 to 4v6
  22. Study sites: 2 to 3v5
  23. Start date changed from estimate of Sep 2021 to Sep 17, 2021v4
  24. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date: Aug 2021 to Sep 2021
    v3
  25. Start date: Jul 2021 to Aug 2021v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Nucleix Ltd.
4 trials monitored
See all monitored trials
Lung Cancer
4,798 trials monitored
See 270 trials at risk
This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.
Trial Details
NCT Number NCT04968548
Lead Sponsor Nucleix Ltd.
Conditions
(from sponsor)		 Lung Cancer
Related terms Lung Neoplasms
Enrollment 6,182 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov